SmartNuclide Overview
- Founded
- 2015
- Status
- Private
- Latest Deal Type
- Series B
- Latest Deal Amount
- $14.1M
- Investors
- 3
SmartNuclide General Information
Description
Developer and researcher of biopharmaceuticals for molecular nuclear oncology. The company specializes in developing innovative biological drug products including both diagnostics and therapeutics formulations targeting molecular oncology, providing reliable and effective products for better cancer treatment.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 218 Xinghu Street, BioBAY A4-202
- Suzhou Industrial Park
- Suzhou, Jiangsu
- China
SmartNuclide Timeline
SmartNuclide Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 23-Apr-2020 | $14.1M | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 12-Nov-2018 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 21-Mar-2016 | Completed | Startup |
SmartNuclide Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Tao Xu | Chief Executive Officer |
SmartNuclide Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Jiuyou Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Longmen Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BOHE Angel Fund | Venture Capital | Minority | 000 0000 | 000000 0 |